1. Pang X, Tang K, He Q, Ma J, et al.
   Longitudinal molecular network analysis in Guangxi: implications for HIV control.
   AIDS 2026.
   


2. Enriquez Canto Y.
   Clinical composition of HIV/AIDS-related deaths during the COVID-19 pandemic: a nationwide natural experiment (2017-2024).
   AIDS 2026.
   


3. Pessoa FS.
   Brazil's historic achievement: WHO certification for eliminating mother-to-child transmission of HIV in a continental nation.
   AIDS 2026;40:539-540.
   


4. Zalesak A, Schnure M, Forster R, Jones JL, et al.
   Targeted cuts to Ryan White programs could raise HIV incidence by 8-17% in 30 US states and the District of Columbia.
   AIDS 2026;40:536-538.
   


5. Rubin LH, Chandra A, Alt J, Dastgheyb RM, et al.
   N-acetyl-aspartyl-glutamate connects neuroinflammatory signatures to attention and working memory in people with HIV.
   AIDS 2026;40:532-535.
   


6. Tao K, Tzou PL, Sahoo MK, Hare CB, et al.
   HIV-1 subtype diversity trends in a Northern California cohort.
   AIDS 2026;40:530-532.
   


7. Goodkin K, Dorfman D.
   Social cognition in people with HIV: a neglected cognitive domain?
   AIDS 2026;40:525-529.
   


8. Soudeyns H.
   High risk of reacquisition of hepatitis C virus infection in people with HIV with continued risk behavior.
   AIDS 2026;40:519-521.
   


9. Subia P, Jiang X.
   The impact of APOE epsilon4 on cognitive performance in adults with HIV: a systematic review and meta-analysis.
   AIDS 2026.
   


10. Lv J, Feng L, Gao L, Yin Z, et al.
    Gray matter asymmetry alterations in perinatally HIV-exposed adolescents: evidence from structural neuroimaging.
    AIDS 2026.
    


11. Barr E, Abuogi L, Lingwall M, Qian Q, et al.
    Breastfeeding support for women with HIV: lactation consultant HIV-knowledge, attitudes, stigma, and tele-lactation experiences.
    AIDS 2026.
    


12. Ciccullo A, Iannone V, Giacomelli A, Baldin G, et al.
    Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort.
    AIDS 2026.
    


13. Crane HM, Dai M, Fredericksen R, Drumright LN, et al.
    Routine collection of patient-reported outcomes in HIV clinics: lessons learned after more than 130,000 assessments have been completed.
    AIDS 2026.
    


14. Nellore A, Bajema K, Belden K, Blumberg D, et al.
    IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients.
    Clin Infect Dis 2026.
    


15. Crumpler M, Realegeno SE, Shakir SM, Hutton SM, et al.
    Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae.
    Clin Infect Dis 2026;82:S19-S35.
    


16. Manabe YC, Smith AC, Trow S, Tran A, et al.
    Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature.
    Clin Infect Dis 2026;82:S43-S51.
    


17. Mitchell KK, Smith AC, Ayala JC, Schmerer MW, et al.
    Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae.
    Clin Infect Dis 2026;82:S36-S42.
    


18. Sterkel AK, Loya TJ, Smith AC, Southern T, et al.
    Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods.
    Clin Infect Dis 2026;82:S6-S12.
    


19. Soge OO, Reimche JL, Smith AC, Schmerer MW, et al.
    Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods.
    Clin Infect Dis 2026;82:S13-S18.
    


20. Smith AC, Kersh EN.
    Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae.
    Clin Infect Dis 2026;82:S1-S5.
    


21. Mohareb AM, Boyd A.
    Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B virus-active Antiretroviral Therapy.
    Clin Infect Dis 2026.
    


22. Pugsley RA, Davis NL, Cope AB, Diesel JC, et al.
    Is three really what we need? Relative effectiveness of benzathine penicillin G and doxycycline treatment regimens for late or unknown duration syphilis in 6 United States jurisdictions, 2016-2021.
    Clin Infect Dis 2026.
    


23. Short WR, Sheth AN, Ciaranello A.
    HIV During Pregnancy and Infant Feeding.
    JAMA 2026.
    


24. Ku C, Pothamsetty N, Lea AN, Alexeeff SE, et al.
    Mammogram Rates Among Women with and without HIV in a Large Integrated Healthcare System.
    J Acquir Immune Defic Syndr 2026.
    


25. O'Shea J, Derton A, Henson J, Iqbal K, et al.
    Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/rilpivirine in the United States, 2021-2023.
    J Acquir Immune Defic Syndr 2026.
    


26. Lee M, Olson A, Pickering RT, Ieong MH, et al.
    Alterations to the bronchial gene-expression effects of tobacco smoking in people living with HIV.
    J Acquir Immune Defic Syndr 2026.
    


27. Haidar L, Crane HM, Nance RM, Doupe MB, et al.
    Impact of SGLT2 Inhibitors on Kidney Function Among People with HIV: A US Prospective Multi-Site Study.
    J Acquir Immune Defic Syndr 2026.
    


28. Ann Schmidt HM, Chan C, Ong J, Tieosapjaroen W, et al.
    The "PrEP APPEAL" of less frequent dosing: acceptability of six-monthly long acting-injectable PrEP among gay and other men who have sex with men and transgender women in Asia.
    J Acquir Immune Defic Syndr 2026.
    


29. Davis SM, Fellows I, de Leon O, Bastani P, et al.
    Circumcision for HIV prevention in men who have sex with men: an updated meta-analysis.
    J Acquir Immune Defic Syndr 2025.
    


30. Sah SS, Kumbhalwar A.
    Comment on "Higher Acceptability of the Monthly Dapivirine Ring Versus Daily Oral Pre-Exposure Prophylaxis Among Adolescent Girls and Young Women in Sub-Saharan Africa in the REACH Trial".
    J Acquir Immune Defic Syndr 2026.
    


31. Pal PB, Elizaldi SR, Diniz GB, Rai RP, et al.
    alpha4 integrin blockade impairs CD8 T cell neuroimmune surveillance following SIV infection.
    J Clin Invest 2026.
    


32. Lou Y, He X, Li G, Sikhondze M, et al.
    CD4-Based Chimeric Antigen Receptor (CAR)-T Cells With Resistance to HIV-1 Infection and Enhanced Anti-HIV Efficacy: Covalent Interaction Between CD4-CAR and HIV-1 Envelope Glycoprotein.
    J Med Virol 2026;98:e70853.
    


33. Stern J, Shepherd RA, Kim Y, Tumpach C, et al.
    Methaneseleninic acid, a circadian-modulating agent, reactivates latent HIV-1 infection without cellular activation or proliferation.
    J Virol 2026.
    


34. Ratevosian J, Beyrer C.
    Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV response.
    Lancet 2026.
    


35. Usaklioglu Erol M, Soguksu P, Kacmaz BB, Mese S, et al.
    Uncovering the Hidden Players: Double-negative T Cells in Pediatric HIV and Their Impact on Disease Progression.
    Pediatr Infect Dis J 2026.
    


36. Natukunda E, Szubert AJ, Bwakura-Dangarembizi M, Mulenga V, et al.
    Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.
    Pediatr Infect Dis J 2026.
    


37. Wise J.
    HIV: Daily pill could help patients simplify complex treatment regimens.
    BMJ 2026;392:s389.
    

Display articles in

• Abstract format